Protein transfer of glycosyl-phosphatidylinositol (GPI)-modified murine B7-1 and B7-2 costimulators

Journal of Immunotherapy

Volumn 22, Issue 5, 1999, Pages 390-400

  Brunschwig, Elaine B ^a,b   Fayen, John D ^a   Edward Medof, M ^a   Tykocinski, Mark L ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Copernicus Gene Systems Inc ^*  (United States)

Author keywords

Cellular cancer vaccine; Cellular engineering; Immunogenic tumor cell; Protein transfer

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD86 ANTIGEN; CHIMERIC PROTEIN; GLUTAMATE AMMONIA LIGASE; GLYCOSYLPHOSPHATIDYLINOSITOL; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE;

ANIMAL CELL; ANTIBODY AFFINITY; ARTICLE; FLOW CYTOMETRY; GENE AMPLIFICATION; GENETIC ENGINEERING; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; TUMOR CELL;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CELL LINE; CHO CELLS; CRICETINAE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; RATS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032884698     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199909000-00002     Document Type: Article

References (69)

1. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T-lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
2. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
3. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler L, Freeman G, Glimcher L. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993;90:5687-90.
4. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-32.
5. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE. B7-l/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with corynebacterium parvum. Cancer Res 1994;54:5420-3.
6. Li Y, McGowan P, Hellstrom L, Hellstrom K, Chen L. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be utilized to treat established mouse melanoma. J Immunol 1994;153:421-8.
7. Townsend S, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994;54:6477-83.
8. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994;179:1205-14.
9. Yang G, Hellstrom KE, Hellstrom I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995;154:2794-800.
10. Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994;54:5552-5.
11. Huang J-H, Getty RR, Chisari FV, Fowler P, Greenspan NS, Tykocinski ML. Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis. Immunity 1994;1:607-13.
12. Brunschwig EB, Levine E, Trefzer U, Tykocinski ML. Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. J Immunol 1995;155:5498-505.
13. McHugh RS, Ahmed SN, Wang Y-C, Sell KW, Selvaraj P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA 1995;92:8059-63.
14. Tykocinski ML, Kaplan DR, Medof ME. Antigen-presenting cell engineering. The molecular toolbox. Am J Pathol 1996;148:1-16.
15. Medof ME, Nagarajan S, Tykocinski ML. Cell surface engineering with GPI-anchored proteins. FASEB J 1996;10:574-86.
16. Li Y, Hellstrom KE, Newby SA, Chen L. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 1996;183:639-44.
17. Tykocinski ML, Shu HK, Ayers DJ, et al. Glycolipid reanchoring of T-lymphocyte surface antigen CD8 using the 3' end sequence of decay-accelerating factor’s mRNA. Proc Natl Acad Sci USA 1988;85:3555-9.
18. Caras IW, Weddell GN, Davitz MA, Nussenzweig V, Martin JDW. Signal for attachment of a phospholipid membrane anchor in decay accelerating factor. Science 1987;238:1280-3.
19. Sleckman BP, Rosenstein Y, Igras VE, Greenstein JL, Burakoff SJ. Glycolipid anchored form of CD4 increases intercellular adhesion but is unable to enhance T cell activation. J Immunol 1991;147:428-31.
20. Brodsky RA, Jane SM, Vanin EF, et al. Purified GPI-anchored CD4:DAF as a receptor for HIV-mediated gene transfer. Human Gene Ther 1994;5:1231-9.
21. Weber MC, Groger RK, Tykocinski ML. A glycosylphosphatidylinositol-anchored cytokine can function as an artificial cellular adhesin. Exp Cell Res 1994;145:1646-52.
22. Lin AY, Devaux B, Green A, Sogerstrom C, Elliot JF, Davis MM. Expression of T-cell antigen receptor heterodimers in a lipid-linked form. Science 1990:249:677-9.
23. Scheirle A, Takacs B, Kremer L, Marin F, Sinigaglia F. Peptide binding to soluble HLA-DR4 molecules produced by insect cells. J Immunol 1992;149:1994-9.
24. Medof ME, Lublin DM, Holers VM, et al. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci USA 1987;84:2007-11.
25. Huang J-H, Greenspan NS, Tykocinski ML. Alloantigenic recognition of artificial glycosylphosphatidylinositol-anchored HLA-A2.1. Mol Immunol 1994;31:1017-28.
26. Freeman GJ, Gray GS, Gimi CD, et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 1991;174:625-31.
27. Glimcher LH, Hamano T, Asofsky R, et al. I-A mutant functional antigen-presenting cell lines. J Immunol 1983;130:2287-94.
28. Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2, a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-11.
29. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9.
30. Gorman CM, Howard BH, Reeves R, et al. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res 1983; 11:7631-48.
31. Davis SJ, Ward HA, Puklavec MJ, Willis AC, Williams AF, Barclay AN. High level expression in Chinese hamster ovary cells of soluble forms of CD4 T lymphocyte glycoprotein including glycosylation variants. J Biol Chem 1990;265:10410-8.
32. Freeman GJ, Borriello F, Hodes RJ, et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med 1993;178:2185-92.
33. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;1:793-801.
34. Walter El, Ratnoff WD, Long KE, Kazura JW, Medof ME. Effect of glycoinositolphospholipid anchor lipid groups on functional properties of decay-accelerating factor protein in cells. J Biol Chem 1992;261:356-62.
35. Ellis JH, Burden MN, Vinogradov DV, Linge C, Crowe JS. Interactions of CD80 and CD86 with CD28 and CTLA4. J Immunol 1996;56:2700-9.
36. Morton PA, Fu X-T, Stewart JA, et al. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). J Immunol 1996;156:1047-54.
37. Truneh A, Reddy M, Ryan P, et al. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis. Mol Immunol 1996;33:321-34.
38. Guo Y, Wu Y, Zhao M, Kong X-P, Liu Y. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain. J Exp Med 1995;181:1345-55.
39. Inobe M, Aoki N, Linsley PS, et al. The role of the B7-la molecule, an alternatively spliced form of murine B7-1 (CD80), on T cell activation. J Immunol 1996;157:582-8.
40. Greenfield EA, Howard E, Paradis T, et al. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding. Implications for induction of antitumor immunity to T cell tumors. J Immunol 1997;158:2025-34.
41. Hollsberg P, Scholz C, Anderson DE, et al. Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4. J Immunol 1997;159:4799-805.
42. Gajewski TF. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol 1996;156:465-72.
43. Doty RT, Clark EA. Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation. J Immunol 1996;157:3270-9.
44. Roberts WL, Myher JJ, Kukis A, Low MG, Rosenberry TL. Lipid analysis of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase: palmitoylation of inositol results m resistance to pnospnoinositoi-speciric pnospnolipase c. J Biol Chem 1988;263:18766-75.
45. Long KE, Yomtovian R, Kida M, Knez JJ, Medof ME. Timedependent loss of surface complement regulatory activity during storage of donor blood. Transfusion 1992;33:294-300.
46. Mold C, Walter El, Medof ME. The influence of membrane components on regulation of alternative pathway activation by decayaccelerating factor. J Immunol 1990;145:3836-41.
47. Caux C, Vanbervliet B, Massacrier C, et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994; 180:1841.
48. Mitra RS, Judge TA, Nestle FO, Turka LA, Nickoloff BJ. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. J Immunol 1995;154:2668-77.
49. Fagnoni FF, Takamizawa M, Godfrey WR, et al. Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells. Immunology 1995;85:467-74.
50. Freeman GJ, Boussiotis VA, Anumanthan A, et al. B7-1 and B7-2 do not deliver identical costimulatory signals since B7-2 but not B7-1 costimulates the initial production of IL-4. Immunity 1995;2:523-32.
51. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Thl/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-10.
52. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995;181:1145-55.
53. Gajewski TF, Fallarino F, Uyttenhove C, Boon T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed oh the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol 1996;156:2909-17.
54. Matulonis U, Dosiou C, Freeman G, et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. J Immunol 1996;156:1126-31.
55. Levine BL, Ueda Y, Craighead N, Huang ML, June CH. CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol 1995;7:891-904.
56. Lanier LL, O’Fallon S, Somoza C, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1994;154:97-105.
57. Inaba K, Witmer-Pack M, Inaba M, et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 1994;180:1849-60.
58. Wu T-C, Huang AYC, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995;182:1415-21.
59. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL. Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J Immunol 1992;149:1115-23.
60. Nandi D, Gross JA, Allison JP. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol 1994;152:3361-9.
61. Steinman R. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
62. Damle NK, Klussman K, Linsley P, Aruffo A. Differential’costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol 1992;148:1985-92.
63. Liu Y, Jones B, Brady W, Janeway CAJ. Co-stimulation of murine CD4-T cell growth: cooperation between B7 and heat-stable antigen. Eur J Immunol 1992;22:2855-9.
64. Cayabyab M, Phillips JH, Lanier LL. CD40 preferentially costimulates activation of CD4+ T lymphocytes. J Immunol 1994;152:1523-31.
65. + T cells with homology to tumor necrosis factor. J Exp Med 1994;180:757-62.
66. DeBenedette MA, Chu NR, Pollok KE, et al. Role of 4-IBB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med 1995;181:985-92.
67. Azuma M, Cayabyab M, Phillips JH, Lanier LL. Requirements for CD28-dependent T cell-mediated cytotoxicity. J Immunol 1993;150:2091-101.
68. Damle NK, Klussman K, Laytze G, et al. Costimulation via vascular cell adhesion molecule-1 induces in T cells increased responsiveness to the CD28 counter-receptor B7. Cell Immunol 1993;148:144-56.
69. Murphy EE, Terres G, Macatonia SE, et al. B7 and IL-12 cooperate for proliferation and IFN gamma production by mouse helper T clones that are unresponsive to B7 costimulation. J Exp Med 1994;180:223-31.